Unicycive Therapeutics (UNCY) Competitors $4.10 +0.16 (+3.93%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. GLUE, ALEC, OCGN, DRUG, SCPH, GALT, TVRD, NGNE, LFCR, and MREOShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Monte Rosa Therapeutics (GLUE), Alector (ALEC), Ocugen (OCGN), Bright Minds Biosciences (DRUG), scPharmaceuticals (SCPH), Galectin Therapeutics (GALT), Tvardi Therapeutics (TVRD), Neurogene (NGNE), Lifecore Biomedical (LFCR), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Monte Rosa Therapeutics Alector Ocugen Bright Minds Biosciences scPharmaceuticals Galectin Therapeutics Tvardi Therapeutics Neurogene Lifecore Biomedical Mereo BioPharma Group Monte Rosa Therapeutics (NASDAQ:GLUE) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Does the media prefer GLUE or UNCY? In the previous week, Unicycive Therapeutics had 14 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 25 mentions for Unicycive Therapeutics and 11 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.25 beat Unicycive Therapeutics' score of 0.10 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Unicycive Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Is GLUE or UNCY more profitable? Monte Rosa Therapeutics has a net margin of 13.58% compared to Unicycive Therapeutics' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics13.58% 9.95% 6.42% Unicycive Therapeutics N/A -243.13%-119.46% Do analysts prefer GLUE or UNCY? Monte Rosa Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 132.50%. Unicycive Therapeutics has a consensus price target of $57.00, suggesting a potential upside of 1,291.94%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more volatility & risk, GLUE or UNCY? Monte Rosa Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Do insiders and institutionals have more ownership in GLUE or UNCY? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 6.5% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, GLUE or UNCY? Unicycive Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M5.39-$72.70M$0.3618.32Unicycive Therapeutics$680K106.35-$36.73M-$4.12-0.99 SummaryMonte Rosa Therapeutics and Unicycive Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.57M$2.53B$5.72B$10.26BDividend YieldN/A57.22%5.72%4.60%P/E Ratio-1.0023.2275.1026.36Price / Sales106.35530.94498.56167.32Price / CashN/A27.5625.8129.90Price / Book5.695.3613.236.29Net Income-$36.73M$32.95M$3.28B$270.30M7 Day Performance-6.51%-0.35%0.32%1.95%1 Month Performance-12.87%4.02%4.73%6.14%1 Year Performance9.11%-2.75%73.16%27.92% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics2.3035 of 5 stars$4.10+3.9%$57.00+1,291.9%-0.3%$72.57M$680K-1.009Analyst ForecastGLUEMonte Rosa Therapeutics2.4642 of 5 stars$4.80-2.8%$15.33+219.4%+14.0%$305.09M$75.62M13.3390Trending NewsALECAlector3.9325 of 5 stars$2.76-8.3%$4.17+51.0%-50.9%$304.65M$100.56M-2.38270Positive NewsAnalyst UpgradeOCGNOcugen1.8882 of 5 stars$1.03flat$6.00+482.5%-0.8%$301.07M$4.05M-5.1580News CoverageDRUGBright Minds Biosciences3.3027 of 5 stars$42.97+1.7%$81.00+88.5%+3,716.5%$297.54MN/A-46.20N/APositive NewsAnalyst ForecastSCPHscPharmaceuticals4.4829 of 5 stars$5.58+0.2%$7.78+39.5%+2.2%$296.87M$36.33M-3.0830Short Interest ↓GALTGalectin Therapeutics1.8453 of 5 stars$4.67+1.5%$6.00+28.5%+56.8%$294.68MN/A-7.309News CoverageTVRDTvardi Therapeutics2.7371 of 5 stars$29.66-4.7%$64.25+116.6%N/A$291.73M$7.14M0.0080NGNENeurogene1.7324 of 5 stars$19.45-2.5%$46.17+137.4%-58.4%$284.73M$930K-4.5190Positive NewsLFCRLifecore Biomedical0.9667 of 5 stars$7.29-3.2%$8.00+9.7%+48.3%$281.68M$128.87M-5.56690MREOMereo BioPharma Group2.361 of 5 stars$1.79+1.1%$7.40+313.4%-58.9%$281.43M$10M-25.5740Positive News Related Companies and Tools Related Companies Monte Rosa Therapeutics Alternatives Alector Alternatives Ocugen Alternatives Bright Minds Biosciences Alternatives scPharmaceuticals Alternatives Galectin Therapeutics Alternatives Tvardi Therapeutics Alternatives Neurogene Alternatives Lifecore Biomedical Alternatives Mereo BioPharma Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredSean Hannity: Help Protect Your RetirementThis Guide to retirement protection has helped thousands protect over $3 billion dollars in retirement savings...Goldco Precious Metals | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UNCY Stock Alerts